Antibacterial resistance poses a global health threat, necessitating innovative drug design and delivery strategies to combat ...

When we go to seek healthcare in hospitals or other healthcare settings, getting infected with hospital-acquired infections ...

Imagine, for a moment, that you have a urinary tract infection (UTI). At first it's just uncomfortable, but pretty quickly it gets really painful. Lying down with a heating pad and drinking lots of ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...

The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to ...

The US Food and Drug Administration has approved a new oral antibiotic for treatment of uncomplicated urinary tract ...

Chief executive of Llusern Scientific, Dr Hayhurst said: “UTI prevalence is rising with an ageing population and the increase ...

The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

On Friday, Iterum Therapeutics plc (NASDAQ:ITRM) received FDA approval for its Orlynvah (sulopenem etzadroxil and probenecid) ...

Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman ...

The treatment has been shown to be active against third generation cephalosporin-resistant Enterobacterales species. Orlynvah combines sulopenem etzadroxil, a penem antibacterial drug, and probenecid, ...

The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and ...